A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer

Molecular Cancer Therapeutics

Volumn 11, Issue 1, 2012, Pages 119-131

  Allen, Wendy L ^a   Stevenson, Leanne ^a   Coyle, Vicky M ^a   Jithesh, Puthen V ^a   Proutski, Irina ^a   Carson, Gail ^a   Gordon, Michael A ^b   Lenz, Heinz Josef D ^b   Van Schaeybroeck, Sandra ^a   Longley, Daniel B ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CASPASE 8; FLICE INHIBITORY PROTEIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PROTEIN; SART1 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; COLORECTAL CANCER; DNA MICROARRAY; DOWN REGULATION; DRUG EFFECT; GENE IDENTIFICATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SYSTEMS BIOLOGY; TUMOR BIOPSY;

ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; RIBONUCLEOPROTEINS, SMALL NUCLEAR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SYSTEMS BIOLOGY;

EID: 84855688769     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0510     Document Type: Article

References (48)

1. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7. (Pubitemid 30162806)
2. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47. (Pubitemid 30036347)
3. Barrier A, Boelle PY, Lemoine A, Tse C, Brault D, Chiappini F, et al. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Dis Colon Rectum 2005;48:2238-48.
4. Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006;24:4685-91. (Pubitemid 46630932)
5. Barrier A, Lemoine A, Boelle PY, Tse C, Brault D, Chiappini F, et al. Colon cancer prognosis prediction by gene expression profiling. Oncogene 2005;24:6155-64. (Pubitemid 43080065)
6. Barrier A, Roser F, Boelle PY, Franc B, Tse C, Brault D, et al. Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 2007;26:2642-8. (Pubitemid 46632008)
7. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005;23:3526-35.
8. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004;22:1564-71. (Pubitemid 41079793)
9. Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007;25:773-80. (Pubitemid 350002876)
10. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9. (Pubitemid 44200649)
11. van de Vijver MJ, HeYD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. Agene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
12. Allen WL, Jithesh PV, Oliver GR, Proutski I, Longley DB, Lenz HJ, et al. The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information. BMC Cancer 2010;10:687.
13. Grigoriadis A, Oliver GR, Tanney A, Kendrick H, Smalley MJ, Jat P, et al. Identification of differentially expressed sense and antisense transcript pairs in breast epithelial tissues. BMC Genomics 2009;10:324.
14. Tanney A, Oliver GR, Farztdinov V, Kennedy RD, Mulligan JM, Fulton CE, et al. Generation of a non-small cell lung cancer transcriptome microarray. BMC Med Genomics 2008;1:20.
15. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, et al. Molecular basis for estrogen receptor alpha deficiency inBRCA1- linked breast cancer. J Natl Cancer Inst 2007;99:1683-94. (Pubitemid 351767217)
16. Allen WL, Coyle VM, Jithesh PV, Proutski I, Stevenson L, Fenning C, et al. Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res 2008;14:6647-55.
17. Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res 2010;16:3378-89.
18. http://www.lgcstandards.com/home/home-en.aspx.
19. Boyer J, McLean E, Aroori S, Wilson P, McCulla A, Carey P, et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004;10:2158-67. (Pubitemid 38375578)
20. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L, et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006;25:838-48. (Pubitemid 43237702)
21. http://www.ebi.ac.uk/arrayexpress/.
22. http://frodo.wi.mit.edu/primer3/.
23. Wilson TR, McEwan M, McLaughlin K, Le Clorennec C, Allen WL, Fennell DA, et al. Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells. Oncogene 2009;28:63-72.
24. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM, et al. c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 2007;67:5754-62. (Pubitemid 46985008)
25. Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K, et al. Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. Cell Death Differ 2009;16:1352-61.
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
27. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
28. Ma W, Stafford LJ, Li D, Luo J, Li X, Ning G, et al. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis. J Cell Biochem 2007;100:1376-86. (Pubitemid 46515572)
29. Xia C, Bao Z, Tabassam F, Ma W, Qiu M, Hua S, et al. GCIP, a novel human grap2 and cyclin D interacting protein, regulates E2F-mediated transcriptional activity. J Biol Chem 2000;275:20942-48. (Pubitemid 30457691)
30. Woodward MJ, de Boer J, Heidorn S, Hubank M, Kioussis D, Williams O, et al. Tnfaip8 is an essential gene for the regulation of glucocorticoid- mediated apoptosis of thymocytes. Cell Death Differ 2010;17:316-23.
31. Kumar D, Whiteside TL. KasidUidentification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin- 1beta-converting enzyme-inhibitory protein. J Biol Chem 2000;275:2973-8. (Pubitemid 30082075)
32. Lee DH, Chung K, Song JA, Kim TH, Kang H, Huh JH, et al. Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells. J Proteome Res 2010;9:5668-76.
33. Sun ZL, Zhu Y, Wang FQ, Chen R, Peng T, Fan ZN, et al. Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim Biophys Acta 2007;1774:764-71.
34. Nibbe RK, Markowitz S, Myeroff L, Ewing R, Chance MR. Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer. Mol Cell Proteomics 2009;8:827-45.
35. Izeradjene K, Douglas L, Delaney A, Houghton JA. Casein kinase II. (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene 2005;24:2050-58. (Pubitemid 40516198)
36. Tapia JC, Torres VA, Rodriguez DA, Leyton L, Quest AF. Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci U S A 2006;103:15079-84. (Pubitemid 44583167)
37. Makarova OV, Makarov EM, Luhrmann R. The 65 and 110 kDa SR-related proteins of the U4/U6.U5 tri-snRNP are essential for the assembly of mature spliceosomes. EMBO J 2001;20:2553-63. (Pubitemid 32452874)
38. Sasatomi T, Suefuji Y, Matsunaga K, Yamana H, Miyagi Y, Araki Y, et al. Expression of tumor rejection antigens in colorectal carcinomas. Cancer 2002;94:1636-41. (Pubitemid 34241098)
39. Gupta M, Mungai PT, Goldwasser E. A new transacting factor that modulates hypoxia-induced expression of the erythropoietin gene. Blood 2000;96:491-97. (Pubitemid 30463367)
40. Koh MY, Darnay BG, Powis G. Hypoxia-associated factor, a novel E3- ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol Cell Biol 2008;28:7081-95.
41. Schimmel J, Balog CI, Deelder AM, Drijfhout JW, Hensbergen PJ, Vertegaal AC. Positively charged amino acids flanking a sumoylation consensus tetramer on the 110kDa tri-snRNP component SART1 enhance sumoylation efficiency. J Proteomics 2010;73:1523-34.
42. Vertegaal AC, Andersen JS, Ogg SC, Hay RT, Mann M, Lamond AI. Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol Cell Proteomics 2006;5:2298-10.
43. Vertegaal AC, Ogg SC, Jaffray E, Rodriguez MS, Hay RT, Andersen JS, et al. A proteomic study of SUMO-2 target proteins. J Biol Chem 2004;279:33791-8. (Pubitemid 39063028)
44. Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, Lemaire F, et al. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 2004;23:2484-98. (Pubitemid 38520746)
45. Kittler R, Putz G, Pelletier L, Poser I, Heninger AK, Drechsel D, et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature 2004;432:1036-40. (Pubitemid 40052235)
46. Olson JE, Wang X, Goode EL, Pankratz VS, Fredericksen ZS, Vierkant RA, et al. Variation in genes required for normal mitosis and risk of breast cancer. Breast Cancer Res Treat 2010;119:423-30.
47. Rogers KM, Thomas M, Galligan L, Wilson TR, Allen WL, Sakai H, et al. Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol Cancer Ther 2007;6:1544-51. (Pubitemid 46954021)
48. Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Lett 2010 Nov 9. [Epub ahead of print].